Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People

Set Alert for People

New Fresenius Kabi Chief Sen Adds Sandoz’ Pawlu

As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.

Appointments Leadership

Neuraxpharm Expands Into The Nordics With New Leader From Viatris

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Europe Appointments

Belgium’s Medaxes Appoints New Board

Belgian industry association Medaxes has appointed a new board at the same time as revealing plans for a biosimilars awareness day in April, following in the footsteps of a recent initiative focused on generics.

Belgium Appointments

Who’s Hired? Stada Names New Specialty Head

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Appointments Strategy

Biocon Biologics Refreshes Management

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.

Appointments Strategy

Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register